4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000054
PRESIDENT AND CFO sold 8,000 shares at an average $78.58 ($628,650)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-08-19 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 104,720 | D: show line 1 in the form |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-08-19 | Sale 10b5-1 | −4,994 | $78.25 | $390,771 | 99,726 | D: show line 2 in the form |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-08-19 | Sale 10b5-1 | −3,006 | $79.14 | $237,880 | 96,720 | D: show line 3 in the form |
| Open-market sales · 8,000 sh · avg $78.58 · $628,650 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-08-19 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 328,827 | D: show line 4 in the form |
Loading xslF345X05/wk-form4_1724186989.xml…